Lilly Reports Results of Tirzepatide in SURPASS-4 Study for Patients with Type 2 Diabetes
Shots: SURPASS-4 study involves assessing tirzepatide (5/10/15mg) vs insulin glargine in 2002 adults in a ratio (1:1:1:3) with T2D inadequately controlled with at least 1 and up to 3 oral antihyperglycemic medications who have increased CV risk The study met its 1EPs and 2EPs led to superior A1C and body weight reductions for both estimands. […]